47% of patients with a mental health disorder receive a different diagnosis within the first ten years of receiving their initial diagnosis.
Those with PTSD are almost twice as likely to develop alcohol use disorder than their peers who have not experienced trauma. Researchers report drugs that block FKBP5, such as benztropine, a drug used to control symptoms of Parkinson's disease, and the experimental compound SAFit2 reduce alcohol preference and drinking in models of PTSD.
Lisdexamfetamine (Vyvanse), a medication commonly used to treat ADHD, lowers the risk of hospitalization and death for those with amphetamine use disorder.
A newly developed vaccine blocks the ability of the opioid Fentanyl's ability to enter the brain, thus blocking the drug's "high".
Based on the criteria set for tobacco addiction, a new study reports that highly-processed foods can be addictive.
Lowering nicotine levels to non-addictive levels reduces smoking without worsening symptoms of depression and anxiety for those suffering from mental health disorders.
Greater impairment of the prefrontal cortex-habenula pathway was correlated with earlier age of first drug use.
Women in their 20's who frequently binge drink had the highest self-reported prevalence of COVID-19 infection among subgroups within a study of alcohol and drug usage during the pandemic. Researchers say the increased infection risk was due to binge drinkers being less vigilant with their social behaviors as a result of intoxication.
Spironolactone, a medication commonly used to lower blood pressure and for treating heart-related problems, shows potential for the treatment of alcohol use disorder.
A new study reports two doses of the psychedelic compound psilocybin reduced heavy alcohol consumption by 83% when combined with therapy for those with alcohol use disorder.